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Investigating the Role of Ca2+ and the Acto-myosin 
Mechanism on the Human MCF-7 Breast Cancer Cell Line
Bri Scherer
Bhupal Bhetwal Ph.D. - Mentor
ABSTRACT
Cancer cells have shown to exhibit enhanced potential to metastasize via 
increased actin-myosin crossbridge formation, which requires increased Ca2+
influx via the voltage-gated calcium channels. 
This then leads to the activation of myosin light chain kinase (MLCK). MLCK 
then phosphorylates myosin light chain and forms the actin-myosin cross 
bridges
Additionally, the PI3-Kinase/Akt pathway is critical for cell survival and 
division, which works from the activation of Akt through phosphorylation of 
PI,4,5BP by PI-3 kinase.
These two critical cell survival pathways have been extensively studied in the 
field of breast cancer cell research and my research is primarily focused on 
investigating the role of VGCC, MLCK and PI-3 kinase on MCF-7 cell viability 
by using pharmacological inhibitors to assess significant changes in 
morphology and cell survival via microscopy and MTT assays. 
AIMS & HYPOTHESES
o Investigate the role of Ca2+-dependent pathway leading to acto-myosin 
cross-bridge formation in MCF-7 cells
o The inhibition of the Ca2+-dependent pathway will decrease viability 
of MCF-7 cells due to the prevention of actin-myosin crossbridge 
formation. 
o Investigate thr role of PI-3 kinase pathway (cell survival pathway) in 
MCF-7 cells
o The inhibition of PI-3 kinase pathway will decrease viability of 





MCF-7 cells were cultured on 96 well plates with 100 ul of media (comprised of DMEM, fetal bovine serum, and antibiotic/antimycotic) in each well and were cultured for 24 
hours to allow the cells to adhere to the plate. Solutions of various concentrations of the drugs were prepared and administered to the wells accordingly, with 1% BME (bitter 
melon extract) being the positive control and EtOH being the negative control. Cells were then allowed to culture for 48-72 hours. Cell viability was assessed via MTT assay and 
morphology via microscopy and compared to the three controls. 
NIFEDIPINE RESULTS
Nifedipine – Voltage-gated Ca2+ blocker Nifedipine is a VGCC inhibitor, and as the concentrations increase, the cell viability decreases. 
The dose-dependent response with the most significant effect was at 40 um. 
PREVIOUS RESEARCH OBTAINED
Prior to investigating the Ca2+-dependent pathway, we investigated the Ca2+-
independent pathway and didn’t find a significant effect when assessing the role of 
ROK and PKC on MCF-7 cell viability. 
Our focus now is to investigate the Ca2+-dependent pathway alongside the PI-3 kinase 
pathway. 
ML-7 RESULTS
ML-7 – Myosin Light Chain Kinase Inhibitor
ML-7 is an MLCK inhibitor, and as the concentrations increase, the cell viability 
decreases. The dose-dependent response with the most significant effect was at 16 um.
FUTURE AIMS
Analyze the KCl with Nifedipine experiment again with smaller doses of KCl compatible with increased 
cell proliferation
Analyze the effects of Wortmannin – a PI-3 Kinase inhibitor on MCF-7 cells
Transfection of MCF-7 cells with siRNA for VGCC knockout for further verification 
Proceed with PCR and Western blotting
NIFEDIPINE + KCl RESULTS 
Nifedipine – VGCC Blocker
KCl – Indirect VGCC Stimulator
KCl exists naturally in the extracellular fluid around 5.5 mm and intracellularly at 140 mm. 
Increasing the amount of KCl extracellularly induces the VGCC to open with an influx of 
Ca2+. Simultaneous administration with Nifedipine should ensure a significant decrease in 
the effect of the calcium. 
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TARGETED HYPOTHESES OF PHARMACOLOGICAL AGENTS
Nifedipine is a VGCC inhibitor.
Application of Nifedipine with varying doses will decrease cell viability because calcium is necessary for the 
formation of the actin-myosin crossbridge and closing the channels deprives the cells of the 
necessary calcium for cell attachment, viability, and migration. 
ML-7 is an MLCK inhibitor
Application of ML-7 with varying doses will decrease cell viability through the inhibition of MLCK 
preventing the phosphorylation of myosin light chain necessary for the actin-myosin crossbridge. 
KCl is an indirect VGCC stimulator 
Application of varying doses of KCl, an indirect VGCC stimulator will allow for the channels to open and 
simultaneous administration of Nifedipine will result in a significant reduction of KCl’s effect.
Wortmannin is a PI-3 Kinase inhibitor
Application of Wortmannin with varying doses will decrease cell viability of the MCF-7 cells through the 
inhibition of PI-3 Kinase and restriction of Akt activation necessary for cell survival and division.
